Alpha Wave Global — 2026 Investments

2 investments dated 2026 · listed companies and verified rows first · show all

Apnimedapnimed.com in 𝕏NASDAQ: APMDJul 2026 · $192M

Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients.

BiotechDigital HealthHealthtechCambridge, US

Lawrence G. Miller(Executive Officer, Director)inDennis Molnar(Executive Officer)Barry Wohl(Chief Business Officer)Ketan Mehta(Head of Product and Engineering, Connected Wearables)Ron Farquhar(Director)Gerald Chan(Director)

Co-investorsHEALTHCARE ROYALTY PARTNERS Morningside Group Sectoral Asset Management

QXOnxtra.inNYSE: QXOApr 2026

Greenwich, US

Ihsan Essaid(Executive Officer)Jason Aiken(Director)Christopher Signorello(Executive Officer)Brad Jacobs(Executive Officer, Director)Valeri Liborski(Executive Officer)Mary Kissel(Director)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.